FTRK
Fast Track Group NASDAQ Listed May 23, 2025$0.43
-4.88%
vs $0.46
Mkt Cap $7.6M
52w Low $0.30
11.8% of range
52w High $1.42
50d MA $0.43
200d MA $0.54
P/E (TTM)
—
EV/EBITDA
—
P/B
—
Debt/Equity
-0.0x
ROE
-2.8%
P/FCF
17.8x
RSI (14)
39.40
ATR (14)
$0.07
Beta
-4.38
50d MA
$0.43
200d MA
$0.54
Avg Volume
63.5K
Fast Track Group provides entertainment-focused event management and marketing services in Singapore, Malaysia, and Thailand. The company operates through Live Entertainment and Agency segments. It engages in the organization and management of live events and concerts by renowned international artistes. The company also provides agency services for artiste endorsements, including artiste broker and supply services to clients. In addition, it offers media planning, public relations management, technical production planning, celebrity sourcing, celebrity engagement consultancy, and event manpower support services. The company was incorporated in 2012 and is based in Singapore.
No. 04-01, 12 Mohamed Sultan Road · Singapore 238961 · SG
No earnings history available.
No analyst ratings available.
No insider trades available.
8-K · 7.01
! Medium
Incannex Healthcare Limited -- 8-K 7.01: Regulation FD Disclosure
Jun 25
8-K · 7.01
! Medium
Neonc Technologies Holdings, Inc. -- 8-K 7.01: Regulation FD Disclosure
NeOnc Technologies Holdings disclosed material information via press release on June 23, 2026, requiring investors to review the furnished exhibit for details on the company announcement.
Jun 23
8-K · 8.01
!! High
Armata Pharmaceuticals, Inc. -- 8-K 8.01: Material Event / Announcement
Jun 23
8-K · 8.01
!! High
Oncolytics Biotech Inc. -- 8-K 8.01: Material Event / Announcement
Jun 16
8-K · 8.01
!! High
Inhibrx Biosciences, Inc. -- 8-K 8.01: Material Event / Announcement
Inhibrx Biosciences' ozekibart has cleared FDA acceptance for a BLA in unresectable/metastatic chondrosarcoma with an April 2027 decision deadline, supporting potential near-term approval and commercialization catalyst.
Jun 15
8-K · 8.01
!! High
Incyte Corporation -- 8-K 8.01: Material Event / Announcement
Jun 8
8-K · 8.01
!! High
INmune Bio, Inc. -- 8-K 8.01: Material Event / Announcement
Jun 2
8-K · 8.01
!! High
NRx Pharmaceuticals, Inc. -- 8-K 8.01: Material Event / Announcement
Jun 2
8-K · 8.01
!! High
Oncolytics Biotech Inc. -- 8-K 8.01: Material Event / Announcement
Jun 1
8-K · 2.02
!! High
Cypherpunk Technologies Inc. -- 8-K 2.02: Earnings Results
May 14
8-K · 7.01
! Medium
Incannex Healthcare Limited -- 8-K 7.01: Regulation FD Disclosure
May 14
8-K · 2.02
!! High
Dogwood Therapeutics, Inc. -- 8-K 2.02: Earnings Results
Dogwood Therapeutics disclosed financial results via 8-K filing, requiring investors to review the attached press release for details on operational performance and financial condition changes.
May 14
8-K · 2.02
!! High
Arbutus Biopharma Corporation -- 8-K 2.02: Earnings Results
May 13
8-K · 2.02
!! High
Corbus Pharmaceuticals Holdings, Inc. -- 8-K 2.02: Earnings Results
May 12
8-K · 8.01
!! High
Coya Therapeutics, Inc. -- 8-K 8.01: Material Event / Announcement
May 12
8-K · 2.02
!! High
Lipocine Inc. -- 8-K 2.02: Earnings Results
Lipocine Inc. reported Q1 2026 financial results, with investors now able to assess the biotech company's operational progress and cash burn rate through March 31.
May 7
8-K · 2.02
!! High
Generate Biomedicines, Inc. -- 8-K 2.02: Earnings Results
Generate Biomedicines reported Q1 2026 financial results, providing investors with updated performance metrics on revenue, expenses, and cash position for the quarter ending March 31, 2026.
May 7
8-K · 2.02
!! High
Cadrenal Therapeutics, Inc. -- 8-K 2.02: Earnings Results
Cadrenal Therapeutics reported Q1 2026 financial results on May 7, 2026, which investors can review in the accompanying press release for operational performance and cash position details.
May 7
8-K · 2.02
!! High
Climb Bio, Inc. -- 8-K 2.02: Earnings Results
Climb Bio reported earnings results via press release, though specific financial metrics aren't detailed in this filing summary, so investors should review the attached exhibit for performance details and guidance.
May 7
8-K · 2.02
!! High
Amylyx Pharmaceuticals, Inc. -- 8-K 2.02: Earnings Results
Amylyx Pharmaceuticals disclosed quarterly earnings results via 8-K filing, with detailed financial performance metrics available in the attached press release exhibit for investor review.
May 7
8-K · 8.01
!! High
Allarity Therapeutics, Inc. -- 8-K 8.01: Material Event / Announcement
Allarity Therapeutics disclosed a material announcement via press release but the 8-K filing does not specify the announcement's content, leaving investors without concrete details on the reported event.
May 6
8-K · 2.02
!! High
Precision BioSciences, Inc. -- 8-K 2.02: Earnings Results
Precision BioSciences reported earnings results via 8-K filing, with complete financial details available in the attached press release exhibit for investors analyzing DTIL/FTRK performance.
May 5
8-K · 7.01
! Medium
Climb Bio, Inc. -- 8-K 7.01: Regulation FD Disclosure
Climb Bio disclosed investor event materials via webcast, indicating the company is providing strategic updates to shareholders through formal disclosure channels.
May 5
8-K · 8.01
!! High
Oncolytics Biotech Inc. -- 8-K 8.01: Material Event / Announcement
Oncolytics Biotech filed a material event disclosure but the specific announcement details are not provided in the summary, limiting investors' ability to assess the significance of this development.
May 4
8-K · 8.01
!! High
Cabaletta Bio, Inc. -- 8-K 8.01: Material Event / Announcement
Cabaletta Bio will present positive early data from its RESET-PV trial at ASGCT 2026, demonstrating rese-cel efficacy in pemphigus vulgaris patients without requiring chemotherapy preconditioning, potentially simplifying treatment.
May 4
8-K
Kymera Therapeutics, Inc. -- 8-K Filing
Kymera Therapeutics (KYMR) reported Q1 2026 results while advancing its oral degrader candidates KT-621 and KT-579 through clinical development, targeting multiple pipeline milestones this year.
Apr 30
8-K · 8.01
!! High
Unknown — 8-K 8.01: Material Event / Announcement
FDA Fast Track designation for imdusiran accelerates hepatitis B development timeline and potential market entry, improving commercialization prospects and de-risking the program for shareholders.
Apr 15
8-K
Unknown — 8-K Filing
Aligos' Fast Track Designation accelerates pevifoscorvir's FDA pathway for hepatitis B, potentially enabling faster approvals and earlier revenue generation if efficacy data proves compelling in ongoing trials.
Apr 14
8-K
Unknown — 8-K Filing
I cannot provide meaningful analysis based on this fragment, as it only contains boilerplate disclaimer language about forward-looking statements with no substantive business information disclosed.
Apr 8
8-K · 8.01
!! High
Unknown — 8-K 8.01: Material Event / Announcement
Oncolytics Biotech (ONCY) may advance pelareorep toward FDA approval for anal cancer, potentially opening a new revenue stream if the pivotal trial succeeds and regulators accept the single-arm study design.
Apr 6
8-K · 8.01
!! High
Unknown — 8-K 8.01: Material Event / Announcement
Context Therapeutics filed an 8-K on April 2, 2026, indicating a material event requiring disclosure, though specific details are unavailable; investors should monitor for subsequent filings clarifying the announcement's business impact.
Apr 2
8-K · 7.01
! Medium
Unknown — 8-K 7.01: Regulation FD Disclosure
Cocrystal disclosed material information via Regulation FD, suggesting significant news requiring immediate public disclosure that could materially impact the stock price and investor decisions.
Apr 2
8-K
Unknown — 8-K Filing
Allarity's FDA Fast Track designation for stenoparib accelerates potential approval timelines and validates clinical efficacy, reducing development risk and increasing probability of market success for this dual-mechanism cancer drug.
Apr 1
8-K
Unknown — 8-K Filing
Cadrenal Therapeutics filed an 8-K with a press release, signaling a material corporate announcement that could impact stock price; investors should review the full press release details to assess the announcement's significance.
Mar 31
8-K
Unknown — 8-K Filing
Akoustis' IND clearance for AKY-2519 Phase 1b trial removes regulatory hurdles and validates the radiopharmaceutical candidate's potential, likely attracting investor interest despite clinical-stage risk.
Mar 30
8-K
Unknown — 8-K Filing
Quoin Pharmaceuticals secured $104.5M in funding and obtained Fast Track designation for QRX003, accelerating development of a rare disease treatment and improving path to commercialization, which should reduce dilution risk and increase probability of clinical success for investors.
Mar 26
8-K · 7.01
! Medium
Unknown — 8-K 7.01: Regulation FD Disclosure
# Analysis: FTRK, MPLT
Companies disclosed material information via press release and presentation on March 26, 2026, signaling potential earnings catalyst or strategic announcement—investors should review exhibits for specifics on forward guidance or operational developments affecting valuations.
Mar 26
8-K · 7.01
! Medium
Unknown — 8-K 7.01: Regulation FD Disclosure
Incannex's sleep medicine partnership enhances clinical credibility and research relationships, potentially accelerating recruitment for sleep apnea trials while building institutional goodwill ahead of product development milestones.
Mar 25
8-K
Unknown — 8-K Filing
ProMIS reported 2025 financial results and corporate updates as a clinical-stage biotech, so investors should monitor cash runway, pipeline progress on neurodegenerative disease antibody candidates, and upcoming clinical trial milestones affecting stock volatility.
Mar 25
8-K · 7.01
! Medium
Unknown — 8-K 7.01: Regulation FD Disclosure
Armata Pharmaceuticals disclosed material information via 8-K filing on March 19, 2026, though specific details aren't provided—investors should review the full disclosure to assess impact on clinical progress, partnerships, or financial position.
Mar 19
8-K · 7.01
! Medium
Unknown — 8-K 7.01: Regulation FD Disclosure
Incannex's $75 million cash position with zero debt provides substantial runway to complete IHL-42X Phase 2 studies and fund Phase 3, reducing financing risk and dilution concerns for shareholders.
Mar 18
8-K
Unknown — 8-K Filing
Alto Neuroscience's strong financial position and advancing neuropsychiatric pipeline entering 2026 suggests reduced near-term dilution risk, potentially supporting stock valuation for clinical-stage investors betting on therapeutic progress.
Mar 16
8-K
Unknown — 8-K Filing
Lyell's Phase 3 trial of ronde-cel versus competitor CAR-T therapies represents a pivotal commercialization milestone that could validate differentiation and significantly expand addressable market if successful.
Mar 12
8-K
Unknown — 8-K Filing
Adicet's strong Phase 1 enrollment and positive autoimmune therapy data suggest clinical progress that could accelerate pipeline advancement and reduce development risk, making the stock attractive for investors betting on gamma delta T-cell therapy success.
Mar 12
8-K · 8.01
!! High
Unknown — 8-K 8.01: Material Event / Announcement
FTRK's drug received FDA Fast Track Designation, enabling expedited development and review that could accelerate market entry, potentially generating revenue sooner and reducing development risk for investors.
Mar 11
8-K
Unknown — 8-K Filing
Cullinan Therapeutics has sufficient cash ($439M runway through 2029) to reach multiple clinical milestones in 2026, reducing near-term financing risk and supporting stock stability despite ongoing development timelines.
Mar 10
8-K
Unknown — 8-K Filing
Artiva Biotherapeutics expects near-term catalysts—AlloNK clinical data and FDA pivotal trial guidance in H1 2026—that could validate its rheumatoid arthritis strategy and drive significant stock appreciation if successful.
Mar 10
8-K
Unknown — 8-K Filing
Taravant's clinical progress and anticipated 2026 milestones suggest potential catalysts for value creation, but investors should await actual regulatory approvals or trial data before committing capital to this cash-burning biotech.
Mar 10
Institutional (13F) — Top 5
All ↗
| # | Manager | Shares | Value | Chg | Period |
|---|---|---|---|---|---|
| 1 | Susquehanna International Group, Llp | 34,419 | $14K | New | Mar 2026 |
| 2 | Ubs Group Ag | 15,159 | $6K | Reduced | Mar 2026 |
| 3 | Citigroup Inc | 5,966 | $5K | New | Dec 2025 |
| 4 | Mcguire Capital Advisors Inc | 2,500 | $1K | New | Mar 2026 |
| 5 | Virtu Financial Llc | 10,233 | $4 | New | Mar 2026 |
Mutual Funds / ETFs (N-PORT) — Top 0
All ↗
No N-PORT holders found.
Valuation
Market Cap
$7.6M
Enterprise Value
$7.3M
P/E (TTM)
—
Forward P/E
—
PEG Ratio
0.12x
P/B
—
P/S
3.46x
P/FCF
17.85x
EV/EBITDA
—
Shares Out
17.5M
Financials (TTM)
Revenue
$2.2M
Net Income
-$2.1M
EBITDA
-$1.8M
Free Cash Flow
$426K
Op Cash Flow
$428K
EPS Basic
$-0.03
EPS Diluted
$-0.10
EPS Forward
—
Gross Margin
27.8%
Op Margin
-98.9%
Net Margin
-93.9%
Balance Sheet
Total Assets
$1.4M
Total Liab.
$2.6M
Total Equity
-$1.2M
Cash
$268K
LT Debt
$0
Book Value/Sh
$-0.07
Debt/Equity
-0.02x
Current Ratio
0.58
Quick Ratio
0.58
Returns & Growth
ROE
-2.8%
ROA
-2.4%
ROIC
47.3%
Rev Growth YoY
-21.5%
EPS Growth YoY
-1463.2%
Price Returns
2W
-14.8%
1M
+41.2%
3M
+2.1%
6M
+17.2%
12M
-90.1%
Technicals
52W High
$1.42
52W Low
$0.30
50d MA
$0.43
200d MA
$0.54
RSI (14)
39.40
ATR (14)
$0.07
Beta
-4.38
Avg Volume
64K
Dividends
Div Rate
$0.00
Div Yield
—
Frequency
—
Ex-Div Date
—
Analyst Price Targets
Consensus
—
High
—
Low
—
Median
—
Data updated apr 25, 2026 10:18am
· Source: financialmodelingprep.com